Stephanie O'Brien
Partner @ Morningside
Stephanie O'Brien is a Series B investor at Morningside focused on Biotechnology and Medical. Stephanie O'Brien represents Morningside Ventures and has extensive experience working with venture-backed technology companies. She focuses on early-stage companies, working with CEOs on building the management team and developing business plans. She has served on numerous private company boards, including ViOptiox, Inc., I-Behavior,Inc., Natural Polymer International Corp., Serica Technology, Inc., Alacer Biomedical, Inc., Inimex Pharmaceuticals, Inc. and BiddingForGood, Inc. She received her A.B., cum laude, from Harvard College and her J.D. from New York University School of Law. Prior to attending law school, Stephanie worked for Chase Manhattan Bank, N.A, where she completed the loan officer credit training program and then worked in international portfolio analysis. After law school, Stephanie spent nine years as a corporate lawyer with Hale and Dorr in the Boston and Washington, D.C. offices, working primarily with venture capital finance and start-up companies.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Stephanie O'Brien invests in
Stages Stephanie O'Brien invests in
Countries Stephanie O'Brien invests in
Investment Focus
Industry
- Biotechnology 2 (33%)
- Medical 1 (17%)
- Auctions 1 (17%)
- Shopping 1 (17%)
- Biopharma 1 (17%)
Stage
- Series B 2 (33%)
- Series C 1 (17%)
- Series D 1 (17%)
- Funding Round 1 (17%)
Country
- United States 2 (33%)
- Canada 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Aduro BioTech
|
Aduro Biotech is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies that are designed to harness the body's natural immune system for the treatment of patients with challenging diseases. It was founded in 2000 and headquartered in Berkeley, California. | $51.4M / Series D / Jan 05, 2015 | |
Inimex Pharmaceuticals
|
Inimex Pharmaceuticals, Inc. is a clinical stage company focused on the development and commercialization of Innate Defense Regulators (IDRs), novel first in class drugs that selectively trigger the body's innate defenses without causing inflammation. | $22M / Series B / Jun 02, 2008 | |
BiddingForGood
|
BiddingForGood is a charitable e-commerce company that connects fundraisers, shoppers and businesses. Online auctions powered by BiddingForGood have generated over $110 million for nonprofit organizations and schools. Many of the top private and public schools and nonprofits in the country use the BiddingForGood platform. The 220,000+ shoppersin our Bidder Community are buying unique and valuable items across our many auctions - all to support the important organizations and causes they care about. Businesses are unlocking new sources of value while managing their philanthropic outreach and impact, and are discovering unique, powerful ways to reach new customers within our community. | $10M / Nov 30, 2005 | |
|
Aduro BioTech
|
Aduro Biotech is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies that are designed to harness the body's natural immune system for the treatment of patients with challenging diseases. It was founded in 2000 and headquartered in Berkeley, California. | Series C | |
|
BiddingForGood
|
BiddingForGood is a charitable e-commerce company that connects fundraisers, shoppers and businesses. Online auctions powered by BiddingForGood have generated over $110 million for nonprofit organizations and schools. Many of the top private and public schools and nonprofits in the country use the BiddingForGood platform. The 220,000+ shoppersin our Bidder Community are buying unique and valuable items across our many auctions - all to support the important organizations and causes they care about. Businesses are unlocking new sources of value while managing their philanthropic outreach and impact, and are discovering unique, powerful ways to reach new customers within our community. | $2.1M | |
|
Aduro BioTech
|
Aduro Biotech is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies that are designed to harness the body's natural immune system for the treatment of patients with challenging diseases. It was founded in 2000 and headquartered in Berkeley, California. | $16.2M / Series B |
Co-Investors
Astellas Venture Management
1 deal together
BC Advantage Funds
1 deal together
BDC Venture Capital
1 deal together
Canaan Partners
1 deal together
Canadian Medical Discoveries Fund
1 deal together
Clough Capital Partners
1 deal together
About Morningside
Morningside makes venture capital investments in companies with novel science and technology. We are characterized by a long-term outlook in company-building and an unwavering commitment to acting ethically. Based in the greater Boston area, our team of entrepreneurial investment professionals has deep experience in life sciences, digital health,AI, materials and technology. Founded in 1986 as a family office for the Chan family, charitable commitments to education, research and healthcare include the Harvard T.H. Chan School of Public Health, the UMass Chan Medical School, and the MIT Morningside Academy for Design.
Morningside Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Gerald Chan
Co-founded
|
|||
Isaac Cheng
Investment Professional
|
|||
Richard Liu
General Partner
|
|||
Ronnie Chan
Co-founder
|
|||
|
Stephanie O'Brien
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Stephanie O'Brien invest in?
Stephanie O'Brien invests primarily in Biotechnology, Medical and Auctions startups, most often at Series B and Series C stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Stephanie O'Brien last invest?
The most recent investment recorded for Stephanie O'Brien closed in Jan 2015. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
